We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
Read MoreHide Full Article
Pfizer (PFE - Free Report) and partner BioNTech (BNTX - Free Report) have announced data from a new analysis which showed that their Omicron BA.4/BA.5-adapted bivalent vaccines elicit a greater increase in neutralizing antibody titers against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 than the original vaccines.
The data showed that a month after a 30-µg booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine was administered, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the companies’ original COVID-19 vaccine. Against emerging Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1, neutralizing antibody titers increased 4.8- to 11.1-fold from pre-booster levels following a booster dose of the bivalent vaccine.
Earlier this month, Pfizer/BioNTech announced updated data from a phase II/III study on its Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. The data showed that BA.4/BA.5 booster elicited substantially higher immune responses against BA.4/BA.5 sublineages compared to the companies’ original COVID-19 vaccine. In individuals older than 55 years of age, the booster produced approximately four-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine.
The companies said that the BA.5 subvariant is still the most prevalent sublineage in the United States. It accounts for nearly 30% of cases while the newly emerging BA.1.1 sublineage accounts for almost 25% of cases.
Pfizer’s stock is down 18.3% this year so far compared with growth of 6.2% for the industry.
Image Source: Zacks Investment Research
BioNTech’s shares are down 35.5% this year so far compared with the industry’s decrease of 19.3%.
Image Source: Zacks Investment Research
Pfizer/BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccines were granted emergency use authorization (EUA) for use as a single booster dose in people aged 12 and above by the FDA in August. In October, the BA.4/BA.5 booster vaccines were authorized for use in kids aged five and above. The “updated booster” contains 15-µg of an mRNA encoding the spike protein present in the original vaccine and 15-µg of an mRNA encoding the spike protein common in the Omicron BA.4 and BA.5 variants.
Along with Pfizer/BioNTech, the FDA authorized Moderna’s (MRNA - Free Report) Omicron BA.4/BA.5-adapted bivalent vaccine for individuals 18 years of age and older.
Last week, Moderna announced data from a phase II/III study in more than 500 adults which showed its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) induced significantly higher neutralizing antibody titers against BA.4/BA.5 subvariants compared to a booster dose of the original COVID vaccine (mRNA-1273). Importantly, the BA.4/BA.5 boosters showed neutralizing titers against emerging subvariant BQ.1.1 in an exploratory analysis
A better-ranked large drugmaker is Merck (MRK - Free Report) , which has a Zacks Rank #1 at present.
Merck’s earnings per share estimates for 2022 have increased from $7.31 per share to $7.38, while that for 2023 have increased from $7.21 per share to $7.34 in the past 30 days. The stock is up 36.0% in the year-to-date period.
Merck beat earnings expectations in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 16.07%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
Pfizer (PFE - Free Report) and partner BioNTech (BNTX - Free Report) have announced data from a new analysis which showed that their Omicron BA.4/BA.5-adapted bivalent vaccines elicit a greater increase in neutralizing antibody titers against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 than the original vaccines.
The data showed that a month after a 30-µg booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine was administered, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the companies’ original COVID-19 vaccine. Against emerging Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1, neutralizing antibody titers increased 4.8- to 11.1-fold from pre-booster levels following a booster dose of the bivalent vaccine.
Earlier this month, Pfizer/BioNTech announced updated data from a phase II/III study on its Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. The data showed that BA.4/BA.5 booster elicited substantially higher immune responses against BA.4/BA.5 sublineages compared to the companies’ original COVID-19 vaccine. In individuals older than 55 years of age, the booster produced approximately four-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine.
The companies said that the BA.5 subvariant is still the most prevalent sublineage in the United States. It accounts for nearly 30% of cases while the newly emerging BA.1.1 sublineage accounts for almost 25% of cases.
Pfizer’s stock is down 18.3% this year so far compared with growth of 6.2% for the industry.
Image Source: Zacks Investment Research
BioNTech’s shares are down 35.5% this year so far compared with the industry’s decrease of 19.3%.
Image Source: Zacks Investment Research
Pfizer/BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccines were granted emergency use authorization (EUA) for use as a single booster dose in people aged 12 and above by the FDA in August. In October, the BA.4/BA.5 booster vaccines were authorized for use in kids aged five and above. The “updated booster” contains 15-µg of an mRNA encoding the spike protein present in the original vaccine and 15-µg of an mRNA encoding the spike protein common in the Omicron BA.4 and BA.5 variants.
Along with Pfizer/BioNTech, the FDA authorized Moderna’s (MRNA - Free Report) Omicron BA.4/BA.5-adapted bivalent vaccine for individuals 18 years of age and older.
Last week, Moderna announced data from a phase II/III study in more than 500 adults which showed its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) induced significantly higher neutralizing antibody titers against BA.4/BA.5 subvariants compared to a booster dose of the original COVID vaccine (mRNA-1273). Importantly, the BA.4/BA.5 boosters showed neutralizing titers against emerging subvariant BQ.1.1 in an exploratory analysis
Zacks Rank and Stocks to Consider
Both Pfizer and BioNTech currently have a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked large drugmaker is Merck (MRK - Free Report) , which has a Zacks Rank #1 at present.
Merck’s earnings per share estimates for 2022 have increased from $7.31 per share to $7.38, while that for 2023 have increased from $7.21 per share to $7.34 in the past 30 days. The stock is up 36.0% in the year-to-date period.
Merck beat earnings expectations in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 16.07%, on average.